LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Article ; Online: Contribution of infection and vaccination to population-level seroprevalence through two COVID waves in Tamil Nadu, India.

    Selvavinayagam, T S / Somasundaram, Anavarathan / Selvam, Jerard Maria / Sampath, P / Vijayalakshmi, V / Kumar, C Ajith Brabhu / Subramaniam, Sudharshini / Kumarasamy, Parthipan / Raju, S / Avudaiselvi, R / Prakash, V / Yogananth, N / Subramanian, Gurunathan / Roshini, A / Dhiliban, D N / Imad, Sofia / Tandel, Vaidehi / Parasa, Rajeswari / Sachdeva, Stuti /
    Ramachandran, Sabareesh / Malani, Anup

    Scientific reports

    2024  Volume 14, Issue 1, Page(s) 2091

    Abstract: This study employs repeated, large panels of serological surveys to document rapid and substantial waning of SARS-CoV-2 antibodies at the population level and to calculate the extent to which infection and vaccination separately contribute to ... ...

    Abstract This study employs repeated, large panels of serological surveys to document rapid and substantial waning of SARS-CoV-2 antibodies at the population level and to calculate the extent to which infection and vaccination separately contribute to seroprevalence estimates. Four rounds of serological surveys were conducted, spanning two COVID waves (October 2020 and April-May 2021), in Tamil Nadu (population 72 million) state in India. Each round included representative populations in each district of the state, totaling ≥ 20,000 persons per round. State-level seroprevalence was 31.5% in round 1 (October-November 2020), after India's first COVID wave. Seroprevalence fell to 22.9% in round 2 (April 2021), a roughly one-third decline in 6 months, consistent with dramatic waning of SARS-Cov-2 antibodies from natural infection. Seroprevalence rose to 67.1% by round 3 (June-July 2021), with infections from the Delta-variant induced second COVID wave accounting for 74% of the increase. Seroprevalence rose to 93.1% by round 4 (December 2021-January 2022), with vaccinations accounting for 63% of the increase. Antibodies also appear to wane after vaccination. Seroprevalence in urban areas was higher than in rural areas, but the gap shrunk over time (35.7 v. 25.7% in round 1, 89.8% v. 91.4% in round 4) as the epidemic spread even in low-density rural areas.
    MeSH term(s) Humans ; India/epidemiology ; COVID-19/epidemiology ; COVID-19/prevention & control ; SARS-CoV-2 ; Seroepidemiologic Studies ; Vaccination ; Antibodies, Viral
    Chemical Substances Antibodies, Viral
    Language English
    Publishing date 2024-01-24
    Publishing country England
    Document type Journal Article
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-023-50338-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Author Correction: Contribution of infection and vaccination to population-level seroprevalence through two COVID waves in Tamil Nadu, India.

    Selvavinayagam, T S / Somasundaram, Anavarathan / Selvam, Jerard Maria / Sampath, P / Vijayalakshmi, V / Kumar, C Ajith Brabhu / Subramaniam, Sudharshini / Kumarasamy, Parthipan / Raju, S / Avudaiselvi, R / Prakash, V / Yogananth, N / Subramanian, Gurunathan / Roshini, A / Dhiliban, D N / Imad, Sofia / Tandel, Vaidehi / Parasa, Rajeswari / Sachdeva, Stuti /
    Ramachandran, Sabareesh / Malani, Anup

    Scientific reports

    2024  Volume 14, Issue 1, Page(s) 5141

    Language English
    Publishing date 2024-03-01
    Publishing country England
    Document type Published Erratum
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-024-55994-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India.

    Malani, Anup / Shah, Daksha / Kang, Gagandeep / Lobo, Gayatri Nair / Shastri, Jayanthi / Mohanan, Manoj / Jain, Rajesh / Agrawal, Sachee / Juneja, Sandeep / Imad, Sofia / Kolthur-Seetharam, Ullas

    The Lancet. Global health

    2020  Volume 9, Issue 2, Page(s) e110–e111

    MeSH term(s) Adolescent ; Adult ; COVID-19/epidemiology ; Child ; Female ; Health Status Disparities ; Humans ; India/epidemiology ; Male ; Middle Aged ; Poverty Areas ; Prevalence ; Residence Characteristics/statistics & numerical data ; Seroepidemiologic Studies ; Young Adult
    Keywords covid19
    Language English
    Publishing date 2020-11-13
    Publishing country England
    Document type Letter
    ZDB-ID 2723488-5
    ISSN 2214-109X ; 2214-109X
    ISSN (online) 2214-109X
    ISSN 2214-109X
    DOI 10.1016/S2214-109X(20)30467-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Seroprevalence of SARS-CoV-2 in slums and non-slums of Mumbai, India, during June 29-July 19, 2020

    Malani, Anup / Shah, Daksha / Kang, Gagandeep / Lobo, Gayatri Nair / Shastri, Jayanthi / Mohanan, Manoj / Jain, Rajesh / Agrawal, Sachee Tainwala / Juneja, Sandeep / Imad, Sofia / Kolthur-Seetharam, Ullas

    Abstract: Objective: Estimate seroprevalence in representative samples from slum and non-slum communities in Mumbai, India, a mega-city in a low or middle-income country and test if prevalence is different in slums. Design: After geographically-spaced community ... ...

    Abstract Objective: Estimate seroprevalence in representative samples from slum and non-slum communities in Mumbai, India, a mega-city in a low or middle-income country and test if prevalence is different in slums. Design: After geographically-spaced community sampling of households, one individual per household was tested for IgG antibodies to SARS-CoV-2 N-protein in a two-week interval. Setting: Slum and non-slum communities in three wards, one each from the three main zones of Mumbai. Participants: Individuals over age 12 who consent to and have no contraindications to venipuncture were eligible. 6,904 participants (4,202 from slums and 2,702 from non-slums) were tested. Main outcome measures: The primary outcomes were the positive test rate for IgG antibodies to the SARS-CoV-2 N-protein by demographic group (age and gender) and location (slums and non-slums). The secondary outcome is seroprevalence at slum and non-slum levels. Sera was tested via chemiluminescence (CLIA) using Abbott Diagnostics ArchitectTM N-protein based test. Seroprevalence was calculated using weights to match the population distribution by age and gender and accounting for imperfect sensitivity and specificity of the test. Results: The positive test rate was 54.1% (95% CI: 52.7 to 55.6) and 16.1% (95% CI: 14.9 to 17.4) in slums and non-slums, respectively, a difference of 38 percentage points (P < 0.001). Accounting for imperfect accuracy of tests (e.g., sensitivity, 0.90; specificity 1.00), seroprevalence was as high as 58.4% (95% CI: 56.8 to 59.9) and 17.3% (95% CI: 16 to 18.7) in slums and non-slums, respectively. Conclusions: The high seroprevalence in slums implies a moderate infection fatality rate. The stark difference in seroprevalence across slums and non-slums has implications for the efficacy of social distancing, the level of herd immunity, and equity. It underlines the importance of geographic specificity and urban structure in modeling SARS-CoV-2.
    Keywords covid19
    Publisher MedRxiv; WHO
    Document type Article ; Online
    Note WHO #Covidence: #20182741
    DOI 10.1101/2020.08.27.20182741
    Database COVID19

    Kategorien

  5. Article: Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India

    Malani, Anup / Shah, Daksha / Kang, Gagandeep / Lobo, Gayatri Nair / Shastri, Jayanthi / Mohanan, Manoj / Jain, Rajesh / Agrawal, Sachee / Juneja, Sandeep / Imad, Sofia / Kolthur-Seetharam, Ullas

    Lancet Glob. Health

    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #922186
    Database COVID19

    Kategorien

  6. Article ; Online: Seroprevalence of SARS-CoV-2 in slums and non-slums of Mumbai, India, during June 29-July 19, 2020

    Malani, Anup / Shah, Daksha / Kang, Gagandeep / Lobo, Gayatri Nair / Shastri, Jayanthi / Mohanan, Manoj / Jain, Rajesh / Agrawal, Sachee Tainwala / Juneja, Sandeep / Imad, Sofia / Kolthur-Seetharam, Ullas

    medRxiv

    Abstract: Objective: Estimate seroprevalence in representative samples from slum and non-slum communities in Mumbai, India, a mega-city in a low or middle-income country and test if prevalence is different in slums. Design: After geographically-spaced community ... ...

    Abstract Objective: Estimate seroprevalence in representative samples from slum and non-slum communities in Mumbai, India, a mega-city in a low or middle-income country and test if prevalence is different in slums. Design: After geographically-spaced community sampling of households, one individual per household was tested for IgG antibodies to SARS-CoV-2 N-protein in a two-week interval. Setting: Slum and non-slum communities in three wards, one each from the three main zones of Mumbai. Participants: Individuals over age 12 who consent to and have no contraindications to venipuncture were eligible. 6,904 participants (4,202 from slums and 2,702 from non-slums) were tested. Main outcome measures: The primary outcomes were the positive test rate for IgG antibodies to the SARS-CoV-2 N-protein by demographic group (age and gender) and location (slums and non-slums). The secondary outcome is seroprevalence at slum and non-slum levels. Sera was tested via chemiluminescence (CLIA) using Abbott Diagnostics ArchitectTM N-protein based test. Seroprevalence was calculated using weights to match the population distribution by age and gender and accounting for imperfect sensitivity and specificity of the test. Results: The positive test rate was 54.1% (95% CI: 52.7 to 55.6) and 16.1% (95% CI: 14.9 to 17.4) in slums and non-slums, respectively, a difference of 38 percentage points (P < 0.001). Accounting for imperfect accuracy of tests (e.g., sensitivity, 0.90; specificity 1.00), seroprevalence was as high as 58.4% (95% CI: 56.8 to 59.9) and 17.3% (95% CI: 16 to 18.7) in slums and non-slums, respectively. Conclusions: The high seroprevalence in slums implies a moderate infection fatality rate. The stark difference in seroprevalence across slums and non-slums has implications for the efficacy of social distancing, the level of herd immunity, and equity. It underlines the importance of geographic specificity and urban structure in modeling SARS-CoV-2.
    Keywords covid19
    Language English
    Publishing date 2020-09-01
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2020.08.27.20182741
    Database COVID19

    Kategorien

  7. Article ; Online: Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India

    Malani, Anup / Shah, Daksha / Kang, Gagandeep / Lobo, Gayatri Nair / Shastri, Jayanthi / Mohanan, Manoj / Jain, Rajesh / Agrawal, Sachee / Juneja, Sandeep / Imad, Sofia / Kolthur-Seetharam, Ullas

    The Lancet Global Health ; ISSN 2214-109X

    2020  

    Keywords General Medicine ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    DOI 10.1016/s2214-109x(20)30467-8
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article ; Online: Seroprevalence in Tamil Nadu through India's two COVID waves: Evidence on antibody decline following infection and vaccination

    Selvavinayagam, T. S. / Somasundaram, Anavarathan / Selvam, Jerard Maria / Ramachandran, Sabareesh / P., Sampath / V., Vijayalakshmi / C., Ajith Brabhu Kumar / Subramanian, Sudharshini / Raju, S. / V., Prakash / N., Yogananth / Subramanian, Gurunathan / A., Roshini / D.N., Dhiliban / Imad, Sofia / Tandel, Vaidehi / Parasa, Rajeswari / Sachdeva, Stuti / Malani, Anup

    medRxiv

    Abstract: Three rounds of population-representative serological studies through India9s two COVID waves (round 1, 19 October-30 November 2020; round 2, 7-30 April 2021; and round 3, 28 June-7 July, 2021) were conducted at the district-level in Tamil Nadu state ( ... ...

    Abstract Three rounds of population-representative serological studies through India9s two COVID waves (round 1, 19 October-30 November 2020; round 2, 7-30 April 2021; and round 3, 28 June-7 July, 2021) were conducted at the district-level in Tamil Nadu state (population 72 million). State-level seroprevalence in rounds 1, 2 and 3 were 31.5%, 22.9%, and 67.1%. Estimated seroprevalence implies that at least 22.6 and 48.1 million persons were infected by the 30 November 2020 and 7 July 2021. There was substantial variation across districts in the state in each round. Seroprevalence ranged from 11.1 to 49.8% (round 1), 7.9 to 50.3% (round 2), and 37.8 to 84% (round 3). Seroprevalence in urban areas was higher than in rural areas (35.7 v. 25.7% in round 1, 74.8% v. 64.1% in round 3). Females had similar seroprevalence to males (30.8 v. 30.2% in round 1, 67.5 v. 65.5% in round 3). While working age populations (age 40-49: 31.6%) had significantly higher seroprevalence than the youth (age 18-29: 30.4%) or elderly (age 70+: 26.5%) in round 1, only the gap between working age (age 40-49: 66.7%) and elderly (age 70+: 59.6%) remained significant in round 3. Seroprevalence was greater among those who were vaccinated for COVID (25.7% v. 20.9% in round 2, 80.0% v. 62.3% in round 3). While the decline in seroprevalence from rounds 1 to 2 suggests antibody decline after natural infection, we do not find a significant decline in antibodies among those receiving at least 1 dose of COVID vaccine between rounds 2 and 3.
    Keywords covid19
    Language English
    Publishing date 2021-11-15
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2021.11.14.21265758
    Database COVID19

    Kategorien

To top